Swiss biopharmaceutical firm Auris Medical has concluded patient enrollment in a Phase III clinical trial (TACTT3) of its product candidate Keyzilen to treat acute and post-acute inner ear tinnitus.

More than 730 European patients have been recruited, with approximately 365 subjects each for the acute tinnitus stage (Stratum A) and the post-acute tinnitus stage (Stratum B).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Formulated in a biocompatible gel, Keyzilen is a small molecule antagonist of N-methyl-D-aspartate (NMDA) receptor currently being developed for delivery through intratympanic injection.

Reported to be involved in tinnitus occurrence, NMDA receptors’ continuous over-expression could result in pathologic excitation of auditory nerve fibres.

Auris Medical founder, chairman and CEO Thomas Meyer said: “Keyzilen has the potential to become the first specific pharmacological treatment for patients with inner ear tinnitus and we look forward to announcing top-line results from TACTT3 early next year.”

“Keyzilen has the potential to become the first specific pharmacological treatment for patients with inner ear tinnitus and we look forward to announcing top-line results from TACTT3 early next year.”

The randomised, double-blind, placebo-controlled Phase III trial will evaluate Keyzilen for the treatment of inner ear tinnitus after traumatic cochlear injury or otitis media.

The protocol for TACTT3 was amended based on the findings from previous Phase III TACTT2 trial.

The primary efficacy endpoints of the TACTT3 trial now include improvement of tinnitus loudness or in tinnitus functional index score.

It is expected that top-line results from the trial will be available in the first quarter of next year.

In addition to Keyzilen, Auris Medical is evaluating AM-111 for acute inner ear hearing loss, AM-101 to treat acute inner ear tinnitus and AM-125 for vestibular disorders such as Meniere’s disease.